Patient Prioritization for Proton Beam Therapy in a Cost-neutral Payer Environment: Use of the Clinical Benefit Score for Resource Allocation.
clinical score
proton therapy
radiation
radiotherapy
resource allocation
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
19 Sep 2019
19 Sep 2019
Historique:
entrez:
14
11
2019
pubmed:
14
11
2019
medline:
14
11
2019
Statut:
epublish
Résumé
Objectives There has been a rapid increase in the number of one- and two-room proton beam therapy (PBT) centers, which may be limited in the number of patients they can treat. The objective of this study was to analyze the impact of the 'clinical benefit score' (CBS), utilized as a method for treatment prioritization for PBT operating in a 'cost-neutral' proton-photon payer environment. Materials & methods This study includes patients considered for PBT at a center that initially had only one or two treatment rooms available for clinical use. Patients were prospectively scored using the CBS, and higher scores were prioritized. The outcome was receipt of PBT and the independent variable was CBS. Crude and adjusted analyses were performed using logistic regression. Results There were 2163 patients evaluated. A total of 205 patients (9.5%) were deemed candidates for PBT, which was received by 122 (5.6%) patients. In patients considered for PBT, the mean CBS was 18.7. Patients who were <21 years old, female, non-Caucasian, receiving re-irradiation, and those with Medicare had a higher CBS. Multivariate analysis adjusting for insurance status revealed both CBS and insurance to be significant predictors for receiving PBT. A unit increase in CBS was associated with 1.04 times increased odds of receiving PBT (OR=1.04, 95%CI: 1.01-1.07, p=0.0145) and having Medicare was associated with 3.13 times increased odds of receiving PBT (OR=3.13, 95%CI: 1.57-6.26, p=0.0012). Subgroup analysis, which only included patients enrolled prior to opening the second gantry, showed 1.05 times increased odds of receiving PBT per unit increase in CBS (OR=1.05, 95%CI: 1.00-1.10, p=0.03) and 2.87 times increased odds of receiving PBT in patients with Medicare (OR=2.87, 95%CI: 1.04-7.92, p=0.04). Conclusion The CBS utilized was significantly associated with the receipt of PBT in a cost-neutral payer setting. Physicians may consider the use of CBS as a resource allocation tool.
Identifiants
pubmed: 31720171
doi: 10.7759/cureus.5703
pmc: PMC6823008
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e5703Informations de copyright
Copyright © 2019, Sharma et al.
Déclaration de conflit d'intérêts
The authors have declared financial relationships, which are detailed in the next section.
Références
Liver Transpl. 2007 Nov;13(11):1564-9
pubmed: 17969210
Hepatology. 2007 Mar;45(3):797-805
pubmed: 17326206
J Clin Oncol. 2004 Jun 1;22(11):2246-50
pubmed: 15169816
J Clin Oncol. 2014 May 20;32(15):1540-2
pubmed: 24752049
Radiother Oncol. 2010 Apr;95(1):45-53
pubmed: 20106540
BMJ Open. 2019 Oct 15;9(10):e025556
pubmed: 31619413
Radiother Oncol. 2012 Apr;103(1):5-7
pubmed: 22326572
Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):499-508
pubmed: 24798985
J Hematol Oncol. 2018 Dec 12;11(1):136
pubmed: 30541578
Br J Neurosurg. 2016 Aug;30(4):382-7
pubmed: 27173123
Radiat Oncol. 2016 May 04;11:66
pubmed: 27142674
Curr Opin Pediatr. 2019 Feb;31(1):28-34
pubmed: 30531222
BMC Health Serv Res. 2005 Oct 31;5:67
pubmed: 16259634
Crit Care Med. 2008 Feb;36(2):414-20
pubmed: 18091539
J Surg Oncol. 2014 Aug;110(2):115-22
pubmed: 24752878
Radiother Oncol. 2007 May;83(2):123-32
pubmed: 17499374
Cancer. 2019 Feb 15;125(4):642-651
pubmed: 30644538
J Clin Oncol. 2018 Aug 20;36(24):2461-2464
pubmed: 29985746